The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients

Summary

Overview article, not a new trial, summarizing evidence that thymosin beta 4 (Tβ4) speeds healing of skin (dermal) wounds. Tβ4 is a naturally occurring repair molecule released by platelets at the site of injury. The article covers full-thickness punch-wound studies in several rodent models and two phase 2 clinical trials in chronic stasis and pressure ulcers. It concerns full-length Tβ4, not TB-500 itself.

Key Findings

• Tβ4 accelerated dermal healing of full-thickness punch wounds in normal rats and mice, steroid-treated rats, diabetic mice and aged mice
• In two phase 2 clinical trials in stasis and pressure ulcers, Tβ4 accelerated healing by almost a month in the patients who did heal
• Tβ4 is released by platelets at the injury site and is described as initiating the repair cascade
• Proposed mechanisms: promoting cell migration and stem cell mobilization and differentiation, and inhibiting inflammation, apoptosis and infection
• The authors conclude Tβ4 is a multifunctional regenerative peptide important in dermal repair

Methodology

Narrative overview in the Annals of the New York Academy of Sciences that summarizes earlier animal wound-model studies and two phase 2 ulcer trials. The abstract does not give patient numbers, doses, formulation or statistical results for the trials.

Limitations

• Summary article; trial details (enrollment, dosing, statistics) are not reported in the abstract
• The “almost a month” faster healing is reported only among patients who healed; the abstract does not say whether more patients healed overall
• Animal results come from acute punch wounds, which differ from chronic ulcers in patients
• Studies used full-length Tβ4, not TB-500, so results cannot be assumed to transfer

Relevance to Content

Summarizes the animal and early (phase 2) human evidence for Tβ4 in skin wound healing. Useful background for TB-500 content, with clear caveats: it concerns full-length Tβ4, trial details are not in the abstract, and the healing benefit was reported among patients who healed.

See Also

• Parent compound: TB-500